Citigroup Cuts Zoetis (NYSE:ZTS) Price Target to $96.00

Zoetis (NYSE:ZTS) had its price objective cut by Citigroup from $112.00 to $96.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages also recently weighed in on ZTS. Piper Sandler lowered their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday. Stifel Nicolaus cut their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. HSBC decreased their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Finally, Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $109.62.

Zoetis Price Performance

Shares of NYSE ZTS opened at $75.62 on Tuesday. The stock’s 50-day simple moving average is $76.41 and its two-hundred day simple moving average is $99.19. Zoetis has a twelve month low of $71.45 and a twelve month high of $160.48. The firm has a market capitalization of $31.25 billion, a P/E ratio of 12.46, a P/E/G ratio of 1.27 and a beta of 0.74. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter last year, the company posted $1.76 EPS. The company’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts anticipate that Zoetis will post 6.19 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 34.93%.

Institutional Investors Weigh In On Zoetis

Institutional investors have recently made changes to their positions in the business. J. Stern & Co. LLP raised its position in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. Norges Bank purchased a new position in shares of Zoetis in the fourth quarter worth about $734,425,000. Vanguard Group Inc. lifted its stake in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. Flossbach Von Storch SE bought a new stake in shares of Zoetis in the 2nd quarter valued at about $302,601,000. Finally, BlackRock Inc. boosted its holdings in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The U.S. Food and Drug Administration granted Emergency Use Authorization for Zoetis’ Simparica Trio to treat New World screwworm infestations in dogs and puppies. The approval expands the product’s potential use and provides Zoetis with an immediate role in addressing a serious animal-health threat. Zoetis Receives Emergency Use Authorization for Simparica Trio
• Positive Sentiment: The FDA decision was reported as the main reason for the stock’s advance, while the product’s established flea-and-tick distribution and veterinary network could help support adoption. Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
• Neutral Sentiment: Zoetis recently reported quarterly adjusted EPS of $1.87, slightly above consensus, but revenue of $2.47 billion fell short of expectations and declined modestly year over year. Management’s full-year 2026 EPS outlook remains $6.15–$6.25, limiting the immediate earnings upside narrative.
• Negative Sentiment: Investor attention remains focused on softer U.S. companion-animal demand, fewer veterinary visits, price-sensitive pet owners and competitive pressure in dermatology and parasiticide products. These concerns have contributed to lower expectations for the company’s recovery. Zoetis slides as investors remain focused on softer pet-care demand and competitive pressure
• Negative Sentiment: BNP Paribas Exane lowered its expectations for Zoetis, while Zacks Research downgraded the stock to “strong sell.” The broader analyst consensus is reported as “hold,” signaling limited confidence in near-term upside. BNP Paribas Exane Has Lowered Expectations for Zoetis Stock Price

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.